VIDEO: Sage Therapeutics plans Alzheimer’s disease trial

SEATTLE — Sage Therapeutics will be starting a randomized, controlled trial in patients with Alzheimer’s disease, Aaron Koenig, MD, the company’s vice president of early clinical development, said at the 2022 American Academy of Neurology annual meeting

“This will complement our work in Parkinson’s disease-mild cognitive impairment, where we will be running a randomized, controlled trial later this year, as well,” he said.